无症状脑膜瘤主动监测与立体定向放射外科的国际多中心配对队列分析:IMPASSE研究
本研究基于10国14个中心的数据,比较无症状脑膜瘤患者接受立体定向放射外科(SRS)与主动监测的影像学与神经学结局。非配对队列中SRS组肿瘤控制率为99.0%,保守组为64.2%(P<.001);1:1倾向匹配后分别为99.4%与62.1%(P<.001)。两组新发神经功能缺损无显著差异。SRS影像学肿瘤控制优于主动监测,且不增加神经功能缺损风险。
要点
- SRS组肿瘤控制率显著高于主动监测组,匹配前后结论一致。
- 两组新发肿瘤相关神经功能缺损发生率无统计学差异。
- SRS与主动监测均为合理选择,SRS可改变无症状脑膜瘤的自然病程。
核心结论
- SRS对无症状脑膜瘤的影像学肿瘤控制优于主动监测,且不增加神经功能缺损风险。
- SRS与主动监测均为合理选择,但SRS似乎改变了无症状脑膜瘤的自然病程,使多数接受治疗患者的肿瘤进展受到控制。
研究设计与样本
- 国际多中心研究,纳入10个国家14个中心的数据,比较SRS与主动监测对无症状脑膜瘤的结局。
- 非配对队列中SRS组727例,平均随访57.2个月;保守管理组388例,平均随访43.5个月。
- 按患者年龄、肿瘤体积、位置和影像随访进行1:1倾向匹配后比较两组结局。
主要发现
- 非配对队列肿瘤控制率:SRS组99.0%,保守组64.2%(P<.001;OR 56.860 [95%CI 26.253-123.150])。
- 非配对队列新发神经功能缺损:SRS组2.5%,保守组2.8%(P=.764;OR 0.890 [95%CI 0.416-1.904])。
- 匹配队列肿瘤控制率:SRS组99.4%,保守组62.1%(P<.001;OR 94.461 [95%CI 23.082-386.568])。
- 匹配队列新发神经功能缺损:SRS组2.3%,保守组3.2%(P=.475;OR 0.700 [95%CI 0.263-1.863])。
临床怎么用
- 对无症状脑膜瘤患者,SRS可作为主动监测之外的控制肿瘤进展的合理选项。
- 决策时需结合患者年龄、肿瘤体积与位置等因素个体化权衡,SRS不增加神经功能缺损风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal management of patients with incidental meningiomas remains unclear. The aim of this study was to characterize the radiologic and neurological outcomes of expectant and stereotactic radiosurgery (SRS) management of asymptomatic meningioma patients. METHODS: Using data from 14 centers across 10 countries, the study compares SRS outcomes to active surveillance of asymptomatic meningiomas. Local tumor control of asymptomatic meningiomas and development of new neurological deficits attributable to the tumor were evaluated in the SRS and conservatively managed groups. RESULTS: In the unmatched cohorts, 727 meningioma patients underwent SRS and were followed for a mean of 57.2 months. In the conservatively managed cohort, 388 patients were followed for a mean of 43.5 months. Tumor control was 99.0% of SRS and 64.2% of conservatively managed patients (P < .001; OR 56.860 [95% CI 26.253-123.150]). New neurological deficits were 2.5% in the SRS and 2.8% of conservatively managed patients (P = .764; OR 0.890 [95% CI 0.416-1.904]). After 1:1 propensity matching for patient age, tumor volume, location, and imaging follow-up, tumor control in the SRS and conservatively managed cohorts was 99.4% and 62.1%, respectively (P < .001; OR 94.461 [95% CI 23.082-386.568]). In matched cohorts, new neurological deficits were noted in 2.3% of SRS-treated and 3.2% of conservatively managed patients (P = .475; OR 0.700 [95% CI 0.263-1.863]). CONCLUSIONS: SRS affords superior radiologic tumor control compared to active surveillance without increasing the risk of neurological deficits in asymptomatic meningioma patients. While SRS and active surveillance are reasonable options, SRS appears to alter the natural history of asymptomatic meningiomas including tumor progression in the majority of patients treated.
引用
- Sheehan J, Pikis S, Islim AI, et al. An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study. Neuro Oncol. 2022. PMID: 34106275. doi:10.1093/neuonc/noab132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。